AstraZeneca antibody cocktail effective in COVID-19: Study |
Clinical News
eMediNexus Coverage from: 
AstraZeneca antibody cocktail effective in COVID-19: Study

1 Read Comments                

An experimental COVID-19 antibody drug cocktail developed by AstraZeneca could reduce severe disease or death in non-hospitalized patients in a late-stage study, stated the drug maker on Monday.The drug, known as AZD7442, was found to decrease the risk of developing severe COVID-19 or death by 50% in patients who had been symptomatic for <7 days. Executive vice president, biopharmaceuticals R&D, AstraZeneca, MenePangalos, said that an early intervention with the antibody drug can signific...
To read the complete article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now